Article Text

other Versions

PDF
Biologic discontinuation studies: a systematic review of methods; authors’ response to van der Maas et al
  1. Kazuki Yoshida1,2,
  2. Yoon-Kyoung Sung1,3,
  3. Arthur Kavanaugh4,
  4. Sang-Cheol Bae3,
  5. Michael E Weinblatt1,
  6. Mitsumasa Kishimoto5,
  7. Kazuo Matsui2,
  8. Shigeto Tohma6,
  9. Daniel H Solomon1
  1. 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Massachusetts, USA
  2. 2Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan
  3. 3Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
  4. 4Division of Rheumatology, Allergy, Immunology, University of California San Diego, La Jolla, California, USA
  5. 5Division of Allergy and Rheumatology, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan
  6. 6Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan
  1. Correspondence to Kazuki Yoshida, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; kazukiyoshida{at}mail.harvard.edu

Statistics from Altmetric.com

We would like to thank van der Maas and colleagues1 for their interest in, and useful feedback on, our review.2 They raise several important points. First, regarding the interpretation of the studies included in the review, we focused on studies examining discontinuation of biologic disease modifying antirheumatic drugs (DMARDs) that examined patient outcomes. Thus, we had difficulty in …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles